Boehringer Can't Halt Production Of Generic Fibrosis Drug
The Unified Patent Court on Thursday refused pharmaceuticals giant Boehringer Ingelheim's attempt to stop a rival from making a generic version of its lung disease medicine, ruling there is no risk...To view the full article, register now.
Already a subscriber? Click here to view full article